Myocardial Perfusion and Scarring in Congenital Heart Disease
- People with congenital heart disease may develop heart failure earlier that those who do not have the disease. One theory to explain this is that the heart s own blood supply may be different in people with congenital heart disease. Problems with this blood supply can severely damage the heart. This damage can be studied with a heart imaging test called a cardiac magnetic resonance imaging (MRI) scan. Researchers want to use this type of scan to look at the blood supply to the heart in people with congenital heart disease.
- To learn more about the blood supply to the heart in people with congenital heart disease.
- Individuals at least 18 years of age who have heart defects caused by congenital heart disease.
- Participants will be screened with a physical exam and medical history. Blood and urine samples will be collected.
- Participants will have a cardiac MRI scan to look at the blood flow to the heart.
- Participants will also have a heart stress test to measure heart function during exercise.
- Other imaging studies of the heart may be performed to collect more information on heart function.
Congenital Heart Disease
|Study Design:||Observational Model: Cohort
Time Perspective: Prospective
|Official Title:||Quantitative Myocardial Perfusion, Myocardial Scarring and Their Contribution to Late Clinical Decompensation in Adults With Congenital Heart Disease|
- Hypothesize that myocardial ischemia, as detectable by quantitative stress perfusion MRI, will predict systolic and diastolic dysfunction in subjects with single ventricle physiology and systemic right ventricles. [ Time Frame: 5 years ]
- A portion of ventricular systolic or diastolic dysfunction will be predictable based on myocardial fibrosis or scarring related to the underlying pathophysiology of single ventricle physiology & systemic right ventricles or post-surgical... [ Time Frame: 5 years ]
- Hypothesize that the combination of cardiac function, stress perfusion abnormalities and myocardial scarring/fibrosis will correlate with symptoms, NYHA functional class and BNP. [ Time Frame: 5 years ]
|Study Start Date:||June 20, 2012|
Please refer to this study by its ClinicalTrials.gov identifier: NCT01639937
|Contact: Marsha Block, R.N.||(301) firstname.lastname@example.org|
|Contact: Andrew E Arai, M.D.||(301) email@example.com|
|United States, District of Columbia|
|Childrens National Medical Center||Recruiting|
|Washington, D.C., District of Columbia, United States|
|United States, Maryland|
|Bethesda, Maryland, United States, 20814|
|National Institutes of Health Clinical Center, 9000 Rockville Pike||Recruiting|
|Bethesda, Maryland, United States, 20892|
|Contact: For more information at the NIH Clinical Center contact Patient Recruitment and Public Liaison Office (PRPL) 800-411-1222 ext TTY8664111010 firstname.lastname@example.org|
|Principal Investigator:||Andrew E Arai, M.D.||National Heart, Lung, and Blood Institute (NHLBI)|